Ignite Creation Date:
2024-05-05 @ 11:19 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002311
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
The Safety of Four Different Dose Levels of Wobenzym in HIV-Positive Patients
Sponsor:
Mucos Pharma GmbH and Co
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
A Phase I-II Dose Escalation Study to Examine the Safety of Four Doses of Wobenzym in HIV Seropositive Patients
Status:
COMPLETED
Status Verified Date:
1993-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To study the safety and efficacy of four different doses of Wobenzym an enzyme combination consisting of pancreatin papain bromelain trypsin lipase amylase chymotrypsin and rutin in patients with HIV infection whose CD4 count is between 250 and 400 cellsmm3 To evaluate the effect of Wobenzym on certain surrogate markers associated with progression of HIV disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: